血管新生型加齢黄斑変性症で Beovu を投与された患者の体液の解像度と有効性を評価するための観察研究 (BLUE SKY)
血管新生加齢黄斑変性症の主要な治療計画の下で Beovu (Brolucizumab) を投与されている患者の体液分解能と有効性を評価するための観察研究
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
調査の概要
詳細な説明
BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".
Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.
All patients were documented either in the AMD or DME-module (Full Analysis Set).
For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Aschersleben、ドイツ、06449
- Novartis Investigative Site
-
Bayreuth、ドイツ、95445
- Novartis Investigative Site
-
Berlin、ドイツ、10713
- Novartis Investigative Site
-
Berlin、ドイツ、14163
- Novartis Investigative Site
-
Bonn、ドイツ、53105
- Novartis Investigative Site
-
Breisach、ドイツ、79206
- Novartis Investigative Site
-
Chemnitz、ドイツ、09113
- Novartis Investigative Site
-
Cologne、ドイツ、50968
- Novartis Investigative Site
-
Dresden、ドイツ、01067
- Novartis Investigative Site
-
Dresden、ドイツ、01324
- Novartis Investigative Site
-
Esslingen am Neckar、ドイツ、73728
- Novartis Investigative Site
-
Glauchau、ドイツ、08371
- Novartis Investigative Site
-
Homburg、ドイツ、66421
- Novartis Investigative Site
-
Hösbach、ドイツ、63768
- Novartis Investigative Site
-
Kiel、ドイツ、24103
- Novartis Investigative Site
-
Leipzig、ドイツ、04106
- Novartis Investigative Site
-
Magdeburg、ドイツ、39104
- Novartis Investigative Site
-
Marienberg、ドイツ、09496
- Novartis Investigative Site
-
Münster、ドイツ、48145
- Novartis Investigative Site
-
Neubrandenburg、ドイツ、17036
- Novartis Investigative Site
-
Schönebeck、ドイツ、39218
- Novartis Investigative Site
-
Stralsund、ドイツ、18435
- Novartis Investigative Site
-
Sulzbach、ドイツ、66280
- Novartis Investigative Site
-
Torgau、ドイツ、04860
- Novartis Investigative Site
-
Waren、ドイツ、17192
- Novartis Investigative Site
-
Würzburg、ドイツ、97080
- Novartis Investigative Site
-
-
Bavaria
-
Munich、Bavaria、ドイツ、81377
- Novartis Investigative Site
-
Neuburg A.d. Donau、Bavaria、ドイツ、86633
- Novartis Investigative Site
-
Würzburg、Bavaria、ドイツ、97080
- Novartis Investigative Site
-
Würzburg、Bavaria、ドイツ、97070
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、60590
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen、Lower Saxony、ドイツ、37075
- Novartis Investigative Site
-
Osnabrück、Lower Saxony、ドイツ、49076
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Rostock、Mecklenburg-Vorpommern、ドイツ、18057
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Trier、Rhineland-Palatinate、ドイツ、54296
- Novartis Investigative Site
-
-
Saarland
-
Saarbrücken、Saarland、ドイツ、66111
- Novartis Investigative Site
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- Novartis Investigative Site
-
Leipzig、Saxony、ドイツ、04103
- Novartis Investigative Site
-
Schneeberg、Saxony、ドイツ、08289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle、Saxony-Anhalt、ドイツ、06118
- Novartis Investigative Site
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07740
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.
説明
Inclusion Criteria:
The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:
- Diagnosis of nAMD or visual impairment due to DME
- Male and Female nAMD and DME patients with ≥18 years of age at index
- Decision to treat with brolucizumab at baseline visit
- Signed written informed consent
- Patients for whom a therapy with brolucizumab was medically indicated
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening
Exclusion Criteria:
- Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
- Patients treated for RVO or CNV other than nAMD
- Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
- Patients participating in parallel in an interventional clinical trial
- Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
- Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
- Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
- Pregnancy and breast-feeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
treatment naïve patients
Patients being the first time treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
|
pre-treated patients
Patients already being treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
時間枠:Month 12
|
This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). |
Month 12
|
|
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
時間枠:Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Morphological CNV-Changes under clinic specific routine treatment schemes
時間枠:Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Percent of patients maintained on q12w dosing after loading through Week 52
時間枠:After loading, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study. |
After loading, month 12
|
|
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
時間枠:Baseline, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. |
Baseline, month 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
時間枠:Baseline
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline
|
|
Evaluate anatomical parameters during treatment with brolucizumab
時間枠:Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
|
Evaluate VA change from baseline during treatment with brolucizumab
時間枠:Baseline, month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Baseline, month 24
|
|
Estimate number of anti-VEGF injections, visits and injection intervals
時間枠:Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate percentage of switchers during first 6 months and characterize switchers
時間枠:Baseline, month 6
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 6
|
|
Estimate discontinuation rate and time to discontinuation
時間枠:Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess retreatment criteria
時間枠:Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the number of OCT
時間枠:Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess the safety of brolucizumab
時間枠:Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate anatomical effectiveness
時間枠:Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate treatment intervals
時間枠:Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Describe implementation of treatment schemes into clinical practice
時間枠:Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
時間枠:Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
時間枠:Month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 12
|
|
Evaluate anatomical parameters during treatment with brolucizumab
時間枠:Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Characterize VA change from baseline during treatment with brolucizumab
時間枠:Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate discontinuation rate during first year of brolucizumab treatment
時間枠:Baseline, month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 12
|
|
Estimate time to discontinuation (persistence)
時間枠:Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the treatment burden
時間枠:Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate the number of OCT and the number of visits with/without OCT
時間枠:Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Month 1-12 and 13-24
|
|
Assess safety of brolucizumab
時間枠:Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。